GSK to acquire BP asset IX from Boston Pharmaceuticals for $2bn.

GSK, a global biopharmaceutical company focused on research and development, agreed to acquire BP asset IX, to obtain rights to efimosfermin alfa - a liver disease drug in late-stage trials, from Boston Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing highly engineered therapies, for $2bn. "I am very proud of today’s agreement with GSK, a company I know and admire with proven expertise in liver disease, and the outstanding work of the Boston Pharmaceuticals team. We are delighted that GSK, a global leader, recognised efimosfermin’s potential to address a growing global public health concern and unmet medical need. Together, we look forward to efimosfermin’s ongoing journey to become a best-in-class treatment for patients with SLD," Elias Zerhouni, Boston Pharmaceuticals Chairman.